User menu

Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.

Bibliographic reference Bryce, A H ; Alumkal, J J ; Armstrong, A ; Higano, C S ; Iversen, P ; et. al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.. In: Prostate Cancer and Prostatic Diseases, Vol. 20, no.2, p. 221-227 (2017)
Permanent URL http://hdl.handle.net/2078.1/184766
  1. Aparicio A. M., Harzstark A. L., Corn P. G., Wen S., Araujo J. C., Tu S.-M., Pagliaro L. C., Kim J., Millikan R. E., Ryan C., Tannir N. M., Zurita A. J., Mathew P., Arap W., Troncoso P., Thall P. F., Logothetis C. J., Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer, 10.1158/1078-0432.ccr-12-3791
  2. Beltran H., Tomlins S., Aparicio A., Arora V., Rickman D., Ayala G., Huang J., True L., Gleave M. E., Soule H., Logothetis C., Rubin M. A., Aggressive Variants of Castration-Resistant Prostate Cancer, 10.1158/1078-0432.ccr-13-3309
  3. Nelson Peter S., Molecular States Underlying Androgen Receptor Activation: A Framework for Therapeutics Targeting Androgen Signaling in Prostate Cancer, 10.1200/jco.2011.39.1300
  4. Gundem Gunes, Van Loo Peter, Kremeyer Barbara, Alexandrov Ludmil B., Tubio Jose M. C., Papaemmanuil Elli, Brewer Daniel S., Kallio Heini M. L., Högnäs Gunilla, Annala Matti, Kivinummi Kati, Goody Victoria, Latimer Calli, O'Meara Sarah, Dawson Kevin J., Isaacs William, Emmert-Buck Michael R., Nykter Matti, Foster Christopher, Kote-Jarai Zsofia, Easton Douglas, Whitaker Hayley C., Neal David E., Cooper Colin S., Eeles Rosalind A., Visakorpi Tapio, Campbell Peter J., McDermott Ultan, Wedge David C., Bova G. Steven, The evolutionary history of lethal metastatic prostate cancer, 10.1038/nature14347
  5. Beer Tomasz M., Armstrong Andrew J., Rathkopf Dana E., Loriot Yohann, Sternberg Cora N., Higano Celestia S., Iversen Peter, Bhattacharya Suman, Carles Joan, Chowdhury Simon, Davis Ian D., de Bono Johann S., Evans Christopher P., Fizazi Karim, Joshua Anthony M., Kim Choung-Soo, Kimura Go, Mainwaring Paul, Mansbach Harry, Miller Kurt, Noonberg Sarah B., Perabo Frank, Phung De, Saad Fred, Scher Howard I., Taplin Mary-Ellen, Venner Peter M., Tombal Bertrand, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, 10.1056/nejmoa1405095
  6. Scher Howard I., Halabi Susan, Tannock Ian, Morris Michael, Sternberg Cora N., Carducci Michael A., Eisenberger Mario A., Higano Celestia, Bubley Glenn J., Dreicer Robert, Petrylak Daniel, Kantoff Philip, Basch Ethan, Kelly William Kevin, Figg William D., Small Eric J., Beer Tomasz M., Wilding George, Martin Alison, Hussain Maha, Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, 10.1200/jco.2007.12.4487
  7. Therasse Patrick, Arbuck Susan G., Eisenhauer Elizabeth A., Wanders Jantien, Kaplan Richard S., Rubinstein Larry, Verweij Jaap, Van Glabbeke Martine, van Oosterom Allan T., Christian Michaele C., Gwyther Steve G., New Guidelines to Evaluate the Response to Treatment in Solid Tumors, 10.1093/jnci/92.3.205
  8. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J., New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), 10.1016/j.ejca.2008.10.026
  9. Armstrong A. J., Garrett-Mayer E. S., Yang Y.-C. O., de Wit R., Tannock I. F., Eisenberger M., A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis, 10.1158/1078-0432.ccr-07-1036
  10. Halabi Susan, Small Eric J., Kantoff Philip W., Kattan Michael W., Kaplan Ellen B., Dawson Nancy A., Levine Ellis G., Blumenstein Brent A., Vogelzang Nicholas J., Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer, 10.1200/jco.2003.06.100
  11. Smaletz Oren, Scher Howard I., Small Eric J., Verbel David A., McMillan Alex, Regan Kevin, Kelly W. Kevin, Kattan Michael W., Nomogram for Overall Survival of Patients With Progressive Metastatic Prostate Cancer After Castration, 10.1200/jco.2002.11.021
  12. Beltran Himisha, Prandi Davide, Mosquera Juan Miguel, Benelli Matteo, Puca Loredana, Cyrta Joanna, Marotz Clarisse, Giannopoulou Eugenia, Chakravarthi Balabhadrapatruni V S K, Varambally Sooryanarayana, Tomlins Scott A, Nanus David M, Tagawa Scott T, Van Allen Eliezer M, Elemento Olivier, Sboner Andrea, Garraway Levi A, Rubin Mark A, Demichelis Francesca, Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, 10.1038/nm.4045
  13. Small Rebecca, Belkora Jeffrey, Jow Alexander, Rabow Michael W., Majure Melanie Catherine, Melisko Michelle E., Chien Amy Jo, Rugo Hope S., Integrating outpatient palliative care into a metastatic breast oncology clinic., 10.1200/jco.2015.33.29_suppl.154
  14. Fitzpatrick John M., Bellmunt Joaquim, Fizazi Karim, Heidenreich Axel, Sternberg Cora N., Tombal Bertrand, Alcaraz Antonio, Bahl Amit, Bracarda Sergio, Di Lorenzo Giuseppe, Efstathiou Eleni, Finn Stephen P., Fosså Sophie, Gillessen Silke, Kellokumpu-Lehtinen Pirkko-Liisa, Lecouvet Frédéric E., Oudard Stephane, de Reijke Theo M., Robson Craig N., De Santis Maria, Seruga Bostjan, de Wit Ronald, Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel, 10.1016/j.ejca.2014.03.010
  15. James Nicholas D, Sydes Matthew R, Clarke Noel W, Mason Malcolm D, Dearnaley David P, Spears Melissa R, Ritchie Alastair W S, Parker Christopher C, Russell J Martin, Attard Gerhardt, de Bono Johann, Cross William, Jones Rob J, Thalmann George, Amos Claire, Matheson David, Millman Robin, Alzouebi Mymoona, Beesley Sharon, Birtle Alison J, Brock Susannah, Cathomas Richard, Chakraborti Prabir, Chowdhury Simon, Cook Audrey, Elliott Tony, Gale Joanna, Gibbs Stephanie, Graham John D, Hetherington John, Hughes Robert, Laing Robert, McKinna Fiona, McLaren Duncan B, O'Sullivan Joe M, Parikh Omi, Peedell Clive, Protheroe Andrew, Robinson Angus J, Srihari Narayanan, Srinivasan Rajaguru, Staffurth John, Sundar Santhanam, Tolan Shaun, Tsang David, Wagstaff John, Parmar Mahesh K B, Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial, 10.1016/s0140-6736(15)01037-5
  16. Sweeney Christopher J., Chen Yu-Hui, Carducci Michael, Liu Glenn, Jarrard David F., Eisenberger Mario, Wong Yu-Ning, Hahn Noah, Kohli Manish, Cooney Matthew M., Dreicer Robert, Vogelzang Nicholas J., Picus Joel, Shevrin Daniel, Hussain Maha, Garcia Jorge A., DiPaola Robert S., Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer, 10.1056/nejmoa1503747
  17. Vale Claire L, Burdett Sarah, Rydzewska Larysa H M, Albiges Laurence, Clarke Noel W, Fisher David, Fizazi Karim, Gravis Gwenaelle, James Nicholas D, Mason Malcolm D, Parmar Mahesh K B, Sweeney Christopher J, Sydes Matthew R, Tombal Bertrand, Tierney Jayne F, Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data, 10.1016/s1470-2045(15)00489-1
  18. Hoskin Peter, Sartor Oliver, O'Sullivan Joe M, Johannessen Dag Clement, Helle Svein I, Logue John, Bottomley David, Nilsson Sten, Vogelzang Nicholas J, Fang Fang, Wahba Mona, Aksnes Anne-Kirsti, Parker Christopher, Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial, 10.1016/s1470-2045(14)70474-7